Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The aim of this study was to compare asparaginase-related toxicities in two asparaginase preparations, namely native Escherichia coli L-asparaginase (L-ASP) and pegylated asparaginase (PEG-ASP) in combination with ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) in natural killer (NK)/T-cell lymphoma (NTCL). Materials and Methods A total of 41 NTCL patients who received IMEP plus native E. coli L-ASP or PEG-ASP at Seoul National University Hospital were included in this study between January 2013 and March 2016. IMEP/ASP treatment consisted of ifosfamide, methotrexate, etoposide, plus native E. coli L-ASP (6,000 IU/m2 on days 1, 3, 5, 7, 9, and 11) or PEG-ASP (2,500 IU/m2 on day 1) every 3 weeks. ASP-related toxicities, toxicity patterns, length of hospital stay, and clinical outcomes were compared between the different treatment groups. Results The frequency of ASP-related toxicities was similar between the IMEP plus native E. coli L-ASP group and the PEG-ASP group apart from hypofibrinogenemia (native E. coli L-ASP vs. PEG-ASP group, 86.4% vs. 36.8%; p=0.001). Although post-treatment transaminase and albumin levels were significantly high and low, respectively, hepatotoxicity gradients before and after treatment did not differ significantly between the groups. Since PEG-ASP was given at an outpatient clinic in some patients, length of hospital stay was significantly shorter in the IMEP plus PEG-ASP group (median, 4.0 vs. 6.0 days; p=0.002). A favorable tendency of clinical outcomes was observed in NTCL patients treated with IMEP plus PEG-ASP (complete remission rate, 73.7% vs. 45.5%; p=0.067). Conclusion IMEP plus PEG-ASP showed similar ASP-related toxicities, shorter length of hospital stay, and a trend towards improved clinical outcomes compared with IMEP plus native E. coli L-ASP in NTCL.
Abstract
Purpose The aim of this study was to compare asparaginase-related toxicities in two asparaginase preparations, namely native Escherichia coli L-asparaginase (L-ASP) and pegylated asparaginase (PEG-ASP) in combination with ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) in natural killer (NK)/T-cell lymphoma (NTCL). Materials and Methods A total of 41 NTCL patients who received IMEP plus native E. coli L-ASP or PEG-ASP at Seoul National University Hospital were included in this study between January 2013 and March 2016. IMEP/ASP treatment consisted of ifosfamide, methotrexate, etoposide, plus native E. coli L-ASP (6,000 IU/m2 on days 1, 3, 5, 7, 9, and 11) or PEG-ASP (2,500 IU/m2 on day 1) every 3 weeks. ASP-related toxicities, toxicity patterns, length of hospital stay, and clinical outcomes were compared between the different treatment groups. Results The frequency of ASP-related toxicities was similar between the IMEP plus native E. coli L-ASP group and the PEG-ASP group apart from hypofibrinogenemia (native E. coli L-ASP vs. PEG-ASP group, 86.4% vs. 36.8%; p=0.001). Although post-treatment transaminase and albumin levels were significantly high and low, respectively, hepatotoxicity gradients before and after treatment did not differ significantly between the groups. Since PEG-ASP was given at an outpatient clinic in some patients, length of hospital stay was significantly shorter in the IMEP plus PEG-ASP group (median, 4.0 vs. 6.0 days; p=0.002). A favorable tendency of clinical outcomes was observed in NTCL patients treated with IMEP plus PEG-ASP (complete remission rate, 73.7% vs. 45.5%; p=0.067). Conclusion IMEP plus PEG-ASP showed similar ASP-related toxicities, shorter length of hospital stay, and a trend towards improved clinical outcomes compared with IMEP plus native E. coli L-ASP in NTCL.
참고문헌 (29)
- Sabattini E, "WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview", Pathologica, 102, pp.83~87 (2010)
- Kwong YL, "CD56+ NK lymphomas: clinicopathological features and prognosis", Br J Haematol, 97, pp.821~829 (1997)[DOI]
- Yamaguchi M, "Frequent expression of P-glycoprotein", MDR1 by nasal T-cell lymphoma cells, 1995, pp.76, 2351~2356
- Kwong YL, "SMILE for natural killer", T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group, 2012, pp.120, 2973~2980
- Yamaguchi M, "Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)", T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study, 2011, pp.29, 4410~4416
- Jaccard A, "Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK", T-cell lymphoma, a phase 2 study, 2011, pp.117, 1834~1839
- Tong WH, "A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia", Blood, 123, pp.2026~2033 (2014)[DOI]
- Pieters R, "L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase", Cancer, 117, pp.238~249 (2011)[DOI]
- Silverman LB, "Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01", Blood, 97, pp.1211~1218 (2001)[DOI]
- Kearney SL, "Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis", Pediatr Blood Cancer, 53, pp.162~167 (2009)[DOI]
- Grace RF, "The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols", Br J Haematol, 152, pp.452~459 (2011)[DOI]
- Henriksen LT, "PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol", Pediatr Blood Cancer, 62, pp.427~433 (2015)[DOI]
- Vrooman LM, "Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study: Dana-Farber Cancer Institute ALL Consortium Protocol 00-01", J Clin Oncol, 31, pp.1202~1210 (2013)[DOI]
- Park YK, "Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct", Anticancer Res, 1, pp.373~376 (1981)
- Stock W, "Prevention and management of asparaginase", pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel, 2011, pp.52, 2237~2253
- Place AE, "Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial", Lancet Oncol, 16, pp.1677~1690 (2015)[DOI]
- Avramis VI, "A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study", Blood, 99, pp.1986~1994 (2002)[DOI]
- Bi XW, "Radiotherapy and PGEMOX", GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK, Ann Hematol, pp.2015, 94[DOI]
- Wang JH, "Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed", refractory extranodal NK, Oncotarget, pp.2016, 7[DOI]
- Asselin BL, "Comparative pharmacokinetic studies of three asparaginase preparations", J Clin Oncol, 11, pp.1780~1786 (1993)[DOI]
- Muller HJ, "Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL", NHL-BFM 95 protocols, 2000, pp.110, 379~384
- Panetta JC, "Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia", Clin Pharmacol Ther, 86, pp.651~658 (2009)[DOI]
- Pileri SA, "Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases", Histopathology, 41, pp.1~29 (2002)
- Kim SJ, "A prognostic index for natural killer cell lymphoma after nonanthracycline-based treatment: a multicentre, retrospective analysis", Lancet Oncol, 17, pp.389~400 (2016)[DOI]
- Lee J, "Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study", J Clin Oncol, 24, pp.612~618 (2006)[DOI]
- Cheson BD, "Revised response criteria for malignant lymphoma", J Clin Oncol, 25, pp.579~586 (2007)[DOI]
- Dinndorf PA, "FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)", Oncologist, 12, pp.991~998 (2007)[DOI]
- Howard SC, "Endocrine complications in pediatric patients with acute lymphoblastic leukemia", Blood Rev, 16, pp.225~243 (2002)[DOI]
- Hongo T, "Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: a retrospective study by the JACLS. Japan Association of Childhood Leukemia Study", Pediatr Int, 44, pp.293~299 (2002)[DOI]